The results support the use of the vaccine regimen of
Johnson & Johnson for the prevention of Ebola virus disease
The Ebola vaccine being developed by Johnson & Johnson just demonstrate a strong immune response in children and adults in a clinical trial underway in Sierra Leone.
The two-dose regimen of this vaccine, according to two studies published today in
«The Lancet Infectious Diseases »Is safe, well tolerated and produces a strong immune response in people over one year of age.
The study EBOVAC-Salone provides relevant new evidence on the potential of the regimen using the Ad26.ZEBOV and MVA-BN-Filo vaccines as a preventive measure against Ebola virus in both children and adults.
Made in Sierra Leone, the study is the first to assess the safety and tolerability of this vaccine regimen in a region affected by the worst Ebola outbreak in West Africa from 2014-2016. He is also the first to have analyzed this regimen In children.
During the outbreak, 28,652 cases and 11,325 deaths by Ebola. About the 20% of cases It occurred in children under the age of 15, and those under the age of five are known to have a higher risk of death than adults.
The authors found the vaccine regimen induced antibody responses against the ebolavirus Zaire21 days later of the second dose in 98% of the participants; furthermore, immune protection persisted in adults for at least two years.
“This study represents an important advance in the development of a vaccination regimen against the Ebola virus in children,” he says. Mohammed Afolabi, author of the study in researcher of the
London School of Medicine and Hygiene (United Kingdom).
And adds. «The results show that it has the potential to save many young lives »
The clinical trial recruited participants from September 2015 to July 2018. The first phase was aimed at get information on safety and immunogenicity of the vaccine and included 43 adults older than 18 years who received the Ad26.ZEBOV vaccine followed by the MVA-BN-Filo vaccine at 56 days.
In the next stage, 400 adults and 576 children and adolescents were vaccinated with this regimen or a single dose of a conjugate vaccine. tetravalent meningococcal followed by placebo at 57 days.
Adults who participated in stage one of the study were offered a booster dose of A26.ZEBOV two years after the first dose that also induced a strong immune response within seven days.
“To protect people from Ebola, we will need a variety of effective interventions. These findings support the strategy of adding a booster dose of Ad26.ZEBOV to previously immunized people at the beginning of an outbreak of Ebola virus disease, “says the researcher. Daniela Manno.
To date, more than 250,000 people participating in clinical trials and vaccination initiatives have received at least the first dose of the Ebola vaccine regimen, including 200,000 who have been fully vaccinated.
Additionally, further studies are underway in Sierra Leone to investigate whether vaccines are safe and induce immune responses among infants under one year of age, and to follow adult and child participants for five years to assess the potential for long term protection.